Search Result

Results for "

endocannabinoid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (1) Biochemical Assay Reagents (1) Cannabinoid Receptor (18) COX (1) Endogenous Metabolite (14) FAAH (6) Fungal (2) GlyT (2) GPR55 (3) Isotope-Labeled Compounds (2) Lipase (1) MAGL (9) PPAR (2) Prostaglandin Receptor (1) Tau Protein (2) TRP Channel (4)
By Research Areas:	Cancer (2) Infection (2) Inflammation/Immunology (8) Metabolic Disease (10) Neurological Disease (26)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148940

Docosahexaenoyl glycerol	Others	Inflammation/Immunology
Docosahexaenoyl glycerol is an analog of endocannabinoid, which stimulates the glucose uptake and exhibits anti-inflammatory efficacy .

HY-162298

γ-Linolenoyl monoethanolamide	Cannabinoid Receptor	Metabolic Disease
γ-Linolenoyl monoethanolamide, a kind of fatty N-acyl ethanolamine, is an endocannabinoid .

HY-165082

Tricosanoyl ethanolamide N-(2-Hydroxyethyl)-tricosanamide	Others	Neurological Disease
Tricosanoyl ethanolamide is a member of endocannabinoids and its structure consists of ethanolamine and tricosanoic acid, which contains 23 carbon atoms. Tricosanoyl ethanolamide can be used for research of diseases related to the endocannabinoid system .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively .

HY-103341

UCM707	Cannabinoid Receptor	Neurological Disease
UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of Anandamide .

HY-114826

Prostaglandin E2-1-glyceryl ester PGE2-1-glyceyl ester	Cannabinoid Receptor	Metabolic Disease Cancer
Prostaglandin E2-1-glyceryl ester, a Prostaglandin Glycerol Ester, is an endocannabinoid ligand for the CB₁ receptor. Prostaglandin E2-1-glyceryl ester induces rapid, transient elevation of intracellular free Ca ²⁺ .

HY-134173

Arachidonoyl ethanolamide phosphate	Cannabinoid Receptor Apoptosis	Neurological Disease
Arachidonoyl ethanolamide phosphate, an endocannabinoid, is an endogenous ligand for cannabinoid receptors in the central nervous system (CB1 subtype) and peripheral immune cells (CB2 subtype) .

HY-162305

MAGL-IN-15	MAGL	Neurological Disease
MAGL-IN-15 (Compound 6) is a MAGL inhibitor that can be used in the research of diseases and disorders related to the regulation of endocannabinoid system signaling activities .

HY-101389

(R)-Methanandamide AM-356	Cannabinoid Receptor TRP Channel	Neurological Disease
(R)-Methanandamide (AM-356), an analog of the endocannabinoid ligand Anandamide, is a potent CB1 agonist with a K_i of 20 nM. (R)-Methanandamide also activates vanilloid (TRPV1) receptors .

HY-113516

20-HETE Ethanolamide	Endogenous Metabolite	Neurological Disease
20-HETE Ethanolamide is a metabolite of endocannabinoid Anandamide. 20-HETE Ethanolamide binds to the rat brain cannabinoid CB1 receptor with a K_i of 985 nM .

HY-125407

Palmitoyl serinol N-Palmitoyl serinol	Cannabinoid Receptor	Inflammation/Immunology
Palmitoyl serinol (N-Palmitoyl serinol) is an analog of the endocannabinoid N-palmitoyl ethanolamine (PEA). Palmitoyl serinol improves the epidermal permeability barrier in both normal and inflamed skin .

HY-101388

AM404 2 Publications Verification	Others	Neurological Disease
AM404, an inhibitor of endocannabinoid reuptake, blocks anandamide transport with IC₅₀ values in the low micromolar range . AM404 is able to relax rat isolated hepatic arteries contracted with Phenylephrine, with a pEC₅₀ value of 7.4 (corresponding to an EC₅₀ of 0.04 μM). Neuroprotective Effect .

HY-103332

N-Arachidonylglycine 1 Publications Verification NA-Gly	GlyT Endogenous Metabolite	Inflammation/Immunology
N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

HY-152148

JZP-MA-11	MAGL	Neurological Disease
JZP-MA-11 is a positron emission tomography (PET) ligand targeting the endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC₅₀ value of 126 nM. JZP-MA-11 can cross the blood-brain barrier (BBB). [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP) .

HY-132310

MAGL-IN-4	MAGL	Neurological Disease
MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC₅₀ of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .

HY-103329

b-AEA MM22; Biotinylated N-arachidonoylethanolamine	Cannabinoid Receptor	Others
b-AEA (MM22) is a biotinylated endocannabinoid analog with probe activity. b-AEA is able to accumulate intracellularly in a similar manner to the parent compound AEA. b-AEA does not interact with other components of the endocannabinoid system and therefore does not interfere with their function. b-AEA can be used to visualize the accumulation and intracellular distribution of endocannabinoids .

HY-113015

Stearoylethanolamide	Endogenous Metabolite	Neurological Disease
Stearoylethanolamide is an endocannabinoid-like compound with pro-apoptotic activity.

HY-10863

Anandamide 1 Publications Verification AEA	Cannabinoid Receptor PPAR TRP Channel GPR55 Fungal Tau Protein Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-121517

URB754	Lipase	Neurological Disease
URB754 is a potent inhibitor of the endocannabinoid-deactivating enzyme monoacylglycerol lipase (MGL) with an IC₅₀ of 200 nM .

HY-103340

O-2093	Cannabinoid Receptor	Neurological Disease
O-2093 is a selective endocannabinoid anandamide (AEA) reuptake inhibitor with IC₅₀ of 17.3 μM .

HY-W747573

N-Linolenoylethanolamine 18:3 NAE; α-Linolenoyl ethanolamide	TRP Channel	Neurological Disease
N-Linolenoylethanolamine (18:3 NAE) is an endocannabinoid. N-Linolenoylethanolamine is a vanillin receptor (TRPV1) agonist .

HY-W020035

L-α-lysophosphatidylinositol (Soy) (sodium)	GPR55	Neurological Disease
L-α-lysophosphatidylinositol Soy sodium is an endogenous ligand of GPR55. L-α-lysophosphatidylinositol Soy sodium is an endogenous lysophospholipid and endocannabinoid neurotransmitter that belongs to the class of lysophospholipids .

HY-138969

(±)10(11)-EDP ethanolamide 10,11-EDP-EA; 10,11-EDP epoxide; 10,11-Epoxy docosapentaenoic ethanolamide	Others	Others
(±)10(11)-EDP ethanolamide (10,11-EDP-EA) (compound C) is an ω-3 endocannabinoid epoxide derivative with antiangiogenic, antitumor and anti-migratory properties in osteosarcoma models.

HY-120300

UCM710	Cannabinoid Receptor	Metabolic Disease
UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase .

HY-110004

ACEA Arachidonyl-2-chloroethylamide	Cannabinoid Receptor	Others
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory .

HY-115358

Lignoceroyl Ethanolamide Tetracosanoic acid monoethanolamide	Endogenous Metabolite	Metabolic Disease
Lignoceroyl ethanolamide is a member of the family of fatty N-acyl ethanolamines collectively called endocannabinoids. Whereas lignoceric acid has been detected at relatively high levels in rat cerebrospinal fluid, the specific role and relative importance of its ethanolamine metabolite have not been determined.

HY-138970

(±)19(20)-EDP ethanolamide 19,20-DHEA epoxide; 19,20-Epoxy docosapentaenoic acid ethanolamide; 19,20-EDP-EA	Others	Others
(±)19(20)-EDP ethanolamide (19,20-DHEA epoxide) (compound 19) is an ω-3 endocannabinoid epoxide with cytokine modulation in neuroinflammation studies, antiangiogenic effects in vascular endothelial cells, and vasodilatory effects on coronary arteries.

HY-138971

(±)17(18)-EpETE-ethanolamide 17,18-EEQ-EA; (±)17,18-EEQ-ethanolamide; (±)17(18)-EpETE-EA	Others	Others
(±)17(18)-EpETE-ethanolamide (17,18-EEQ-EA) (compound 17) is an ω-3 endocannabinoid epoxide with cytokine modulation in neuroinflammation studies, antiangiogenic effects in vascular endothelial cells, and vasodilatory effects on coronary arteries.

HY-151107

CBR Agonist-2	Cannabinoid Receptor	Neurological Disease
CBR Agonist-2 is a CB1 agonist (CB1R; CB1 ligand) with an EC₅₀ and a K_i of 960 nM and 970 nM, respectively. CBR Agonist-2 is a promising tool for investigating the involvement of hCB1R in disorders associated with the endocannabinoid system .

HY-112528

Glycerophospho-N-palmitoyl ethanolamine GP-NPEA	Others	Metabolic Disease
Glycerophospho-N-palmitoyl ethanolamine (GP-NPEA) is a metabolic precursor of palmitoyl ethanolamide PEA (HY-157829). Glycerophospho-N-palmitoyl ethanolamine decreases in the cortex of CUMS rats, which may be related to a disorder in the endocannabinoid system arising after the onset of depression .

HY-133130

JNJ-42226314	MAGL	Neurological Disease
JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .

HY-125407S

Palmitoyl serinol-d5 N-Palmitoyl serinol-d₅	Cannabinoid Receptor	Inflammation/Immunology
Palmitoyl serinol-d₅ is the deuterium labeled Palmitoyl serinol[1]. Palmitoyl serinol (N-Palmitoyl serinol) is an analog of the endocannabinoid N-palmitoyl ethanolamine (PEA). Palmitoyl serinol improves the epidermal permeability barrier in both normal and inflamed skin[2][3].

HY-146342

FAAH/MAGL-IN-3	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC₅₀ values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .

HY-146341

FAAH-IN-5	FAAH MAGL	Neurological Disease
FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .

HY-116418

Virodhamine	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

HY-N0313

Euphol	MAGL Endogenous Metabolite	Inflammation/Immunology
Euphol is a tetracyclic triterpene alcohol isolated from the sap of Euphorbia tirucalli with anti-mutagenic, anti-inflammatory and immunomodulatory effects, orally active. Euphol inhibits the monoacylglycerol lipase (MGL) activity via a reversible mechanism (IC₅₀=315 nM). MGL inhibition in the periphery modulates the endocannabinoid system to block the development of inflammatory pain .

HY-110194

Virodhamine TFA	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine TFA is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine TFA induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine TFA can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

HY-103463

SA57	FAAH MAGL	Neurological Disease
SA57 is a potent, selective FAAH inhibitor with IC₅₀s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC₅₀s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC₅₀ of 850 nM), but not other brain serine hydrolases .

HY-150029

CB1/2 agonist 3	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a CB1/CB2 (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with K_i values of 5.9 nM and 3.5 nM, respectively .

HY-121996

Prostaglandin E2 Ethanolamide PGE2 ethanolamide	Prostaglandin Receptor COX	Inflammation/Immunology
Prostaglandin E2 Ethanolamide (PGE₂-EA), an analog of PGE2, can be formed enzymatically following COX-2 oxygenation of endocannabinoids. Prostaglandin E2 Ethanolamide (PGE₂-EA) could modulate the production of the proinflammatory cytokine TNF-α in human blood and human monocytic cells .

HY-77491

FAAH/MAGL-IN-5	FAAH MAGL	Neurological Disease
AM6701 is a potent FAAH/MAGL inhibitor (equipotent inhibitory IC₅₀: 1.2 nM) with neuroprotective effects .

HY-120961

Oleoyl ethyl amide N-Ethyloleamide	FAAH	Metabolic Disease
Oleoyl ethyl amide (N-Ethyloleamide) is a fatty acid amide hydrolase (FAAH) inhibitor. Oleoyl ethyl amide can counteract bladder overactivity .

HY-120965

N-Palmitoyl Taurine	Endogenous Metabolite	Metabolic Disease
Several different arachidonoyl amino acids, including N-arachidonoyl dopamine (NADA) and N-arachidonoyl serine (ARA-S), have been isolated and characterized from bovine brain.1 During mass spectral lipidomic analysis of rat brain, a series of fatty acyl amides of a third amino acid, taurine, is discovered. N-Palmitoyl taurine is a prominent amino-acyl endocannabinoid isolated from rat brain during lipidomics profiling. Its function is currently under investigation.

HY-103332S

N-Arachidonylglycine-d8 NA-Gly-d₈	Isotope-Labeled Compounds Endogenous Metabolite GlyT	Inflammation/Immunology
N-Arachidonylglycine-d8 is a deuterated labeled N-Arachidonylglycine . N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

HY-10865

LY2183240 2 Publications Verification	FAAH Autophagy	Neurological Disease
LY2183240 is a highly potent blocker of anandamide uptake (IC₅₀= 270 pM; K_i=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC₅₀ of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC₅₀s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively .

HY-10863S

Anandamide-d8 AEA-d₈	Isotope-Labeled Compounds Cannabinoid Receptor PPAR Endogenous Metabolite Tau Protein GPR55 Fungal TRP Channel	Infection
Anandamide-d8 is a deuterated labeled Anandamide . Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-120963

N-Oleoyl Taurine	Endogenous Metabolite	Metabolic Disease
Several different arachidonoyl amino acids, including N-arachidonoyl dopamine and N-arachidonoyl serine, have been isolated and characterized from bovine brain.1 During mass spectral lipidomics analysis of rat brain, a series of fatty acyl amides of a third amino acid, taurine, were discovered.2 This novel class of compounds is present in kidney and activates members of the transient receptor potential (TRP) family of calcium channels.3 N-Oleoyl taurine is an amino-acyl endocannabinoid isolated from rat brain that may activate TRPV1 and TRPV4.

HY-120964

N-Stearoyl Taurine	Endogenous Metabolite	Metabolic Disease
Several different arachidonoyl amino acids, including N-arachidonoyl dopamine (NADA) and N-arachidonoyl serine (ARA-S), have been isolated and characterized from bovine brain.1 During mass spectral lipidomic analysis of rat brain, a series of fatty acyl amides of a third amino acid, taurine, is discovered.2 This novel class of compounds is present in kidney and activates members of the transient receptor potential (TRP) family of calcium channels.3 N-Stearoyl taurine is a prominent amino-acyl endocannabinoid isolated from rat brain during lipidomics profiling.

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine	Biochemical Assay Reagents	Others
Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

Cat. No.	Product Name	Type

HY-110004

ACEA Arachidonyl-2-chloroethylamide	Cell Assay Reagents
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory .

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine

Drug Delivery

Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

Cat. No.	Product Name	Target	Research Area

HY-134545

N-Arachidonoyl-L-alanine NALA	Peptides	Cancer
N-Arachidonoyl-L-alanine is an endocannabinoid analog with anti-cancer effects. N- Arachidonoyl-L-alanine kills HNSCC cells through 5-LO-mediated ROS productio .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-103332

N-Arachidonylglycine 1 Publications Verification NA-Gly	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	GlyT Endogenous Metabolite
N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

HY-113015

Stearoylethanolamide	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Endogenous Metabolite
Stearoylethanolamide is an endocannabinoid-like compound with pro-apoptotic activity.

HY-10863

Anandamide 1 Publications Verification AEA	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Cannabinoid Receptor PPAR TRP Channel GPR55 Fungal Tau Protein Endogenous Metabolite
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-116418

Virodhamine	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Cannabinoid Receptor
Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

HY-N0313

Euphol	Triterpenes Structural Classification Classification of Application Fields Terpenoids Euphorbiaceae Plants Inflammation/Immunology Disease Research Fields	MAGL Endogenous Metabolite
Euphol is a tetracyclic triterpene alcohol isolated from the sap of Euphorbia tirucalli with anti-mutagenic, anti-inflammatory and immunomodulatory effects, orally active. Euphol inhibits the monoacylglycerol lipase (MGL) activity via a reversible mechanism (IC₅₀=315 nM). MGL inhibition in the periphery modulates the endocannabinoid system to block the development of inflammatory pain .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Cannabinoid Receptor Endogenous Metabolite
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively .

HY-113516

20-HETE Ethanolamide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
20-HETE Ethanolamide is a metabolite of endocannabinoid Anandamide. 20-HETE Ethanolamide binds to the rat brain cannabinoid CB1 receptor with a K_i of 985 nM .

Cat. No.	Product Name	Chemical Structure

HY-103332S

N-Arachidonylglycine-d8

N-Arachidonylglycine-d8 is a deuterated labeled N-Arachidonylglycine . N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

HY-10863S

Anandamide-d8

Anandamide-d8 is a deuterated labeled Anandamide . Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-125407S

Palmitoyl serinol-d5
Palmitoyl serinol-d₅ is the deuterium labeled Palmitoyl serinol[1]. Palmitoyl serinol (N-Palmitoyl serinol) is an analog of the endocannabinoid N-palmitoyl ethanolamine (PEA). Palmitoyl serinol improves the epidermal permeability barrier in both normal and inflamed skin[2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks